Ironwood Pharmaceuticals INC Form 4 insider transactions

Jeffrey Silber, SVP, CMO, Head-Res&Drug of Ironwood Pharmaceuticals Inc, received 137,036 shares of common stock on July 20, 2026.

Ronald Silver, an officer at Ironwood Pharmaceuticals, reported a sale of 127,890 shares of Class A Common Stock on July 7, 2026, executed under a Rule 10b5-1 trading plan.

Ironwood Pharmaceuticals Director Jay Shepard reported a transaction involving Class A Common Stock on June 16, 2026.

Marla L. Kessler, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Mark G. Currie, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Duane R. Jon, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Alexander J. Denner, a Director at Ironwood Pharmaceuticals, reported transactions involving Class A Common Stock, acquiring shares under the company's director compensation policy.

Ironwood Pharmaceuticals Director Julie McHugh reports transactions involving Class A Common Stock, including the acquisition of restricted stock and the sale of shares under a 10b5-1 plan.

Catherine Moukheibir, a Director at Ironwood Pharmaceuticals, reported a transaction involving Class A Common Stock on June 16, 2026.

Ronald Silver, a Principal Financial and Accounting Officer at Ironwood Pharmaceuticals, reported a transaction involving 25,000 shares of common stock.

Ironwood Pharmaceuticals director Alexander J. Denner reported the acquisition of shares through a compensation policy and significant indirect sales of common stock.

Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, was granted 136,612 Class A Common Stock restricted stock units as an annual performance award.

Ironwood Pharmaceuticals' CFO, Gregory S. Martini, was granted 136,612 shares of Class A Common Stock as a restricted stock unit award.

Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L. Gaskins, acquired 136,612 shares of Class A Common Stock through a performance-based restricted stock unit award.

Michael Shetzline, SVP at Ironwood Pharmaceuticals, received an annual performance award of 136,612 restricted stock units.

Ronald Silver, Principal Accounting Officer at Ironwood Pharmaceuticals, received a grant of 163,934 Class A Common Stock as a performance award.

Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' SVP, CMO, and Head of Research & Drug Development, Michael Shetzline, sold 32,582 shares to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L. Gaskins, sold over 21,000 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals CEO Thomas A. McCourt reported non-discretionary sales of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' CFO, Gregory S. Martini, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' Principal Accounting Officer, Ronald Silver, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' Principal Accounting Officer, Ronald Silver, sold 35,416 shares of Class A Common Stock at $4.6 per share under a pre-arranged 10b5-1 trading plan.

Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc., received a grant of 4,178 shares of Class A Common Stock.

Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L Gaskins, sold 6,016 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals Director Alexander Denner acquired 11,718 shares of Class A Common Stock, while his indirect beneficial ownership decreased due to an advisory agreement termination.

Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L Gaskins, sold 1,316 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' CFO, Gregory S. Martini, sold 1,265 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, sold 7,754 shares of Class A Common Stock to cover tax withholding obligations.

Ironwood Pharmaceuticals' Principal Accounting Officer, Ronald Silver, sold 2,846 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.